Repatha Cost in Oklahoma 2026: Prices, Insurance, Medicaid, and Compounding

What Does Repatha Actually Cost in Oklahoma in 2026?

The Amgen wholesale acquisition price for Repatha (evolocumab) in 2026 is approximately $580 per month for the 140 mg/mL single-dose autoinjector, and Oklahoma retail pharmacies reflect that figure almost exactly at the cash-pay counter. That number has remained relatively flat since Amgen introduced a list-price cut in 2018, dropping the drug from its original launch price of over $14,000 per year to closer to $7,000 per year [1]. The 420 mg monthly cartridge for the SureClick device carries a nearly identical monthly cost.

Without insurance or assistance programs, a patient paying out of pocket in Tulsa or Oklahoma City faces roughly $6,960 per year. That is a substantial burden for a medication taken indefinitely in most ASCVD or familial hypercholesterolemia cases. The FDA-approved prescribing information confirms that evolocumab is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or established cardiovascular disease who require additional LDL-C lowering [2].

The FOURIER trial (N=27,564) published in the New England Journal of Medicine demonstrated a 59% mean reduction in LDL-C at 48 weeks compared to placebo, along with a 15% relative risk reduction in the composite cardiovascular endpoint of heart attack, stroke, and cardiovascular death [3]. That magnitude of effect gives prescribers a strong clinical rationale for prioritizing access, which makes the cost question especially pressing for Oklahoma patients.

For context, the American College of Cardiology and American Heart Association 2019 cholesterol guidelines state: "For patients with very high-risk ASCVD and LDL-C levels <70 mg/dL who are already on maximally tolerated statin therapy plus ezetimibe, a PCSK9 inhibitor may be considered" [4]. That recommendation places evolocumab squarely within guideline-supported care for a defined, high-risk population.

Does Oklahoma Medicaid Cover Repatha?

Oklahoma Medicaid (SoonerCare) does not cover Repatha for the majority of enrolled members under its 2026 preferred drug list. This is not an administrative oversight. PCSK9 inhibitors as a class have faced restricted formulary placement across many state Medicaid programs due to acquisition cost relative to statin alternatives. A 2020 analysis published in JAMA Cardiology found that PCSK9 inhibitor coverage under state Medicaid programs varied widely, with many states requiring multiple prior authorization steps or excluding the class entirely [5].

SoonerCare members who believe they qualify for an exception can submit a prior authorization request through their prescribing provider. The prescriber must document statin intolerance or confirmed familial hypercholesterolemia, typically with genetic or clinical DLCN criteria. Approval rates for PA requests in this class remain low in states without explicit formulary inclusion [6].

Oklahoma also has a separate Children's Medicaid program (SoonerCare Choice) and a separate aged, blind, and disabled population pathway. Neither pathway lists evolocumab as a covered drug in 2026. Patients who receive partial dual coverage through Medicare Advantage plans may have better luck, since Medicare Part D coverage for evolocumab varies by plan and is subject to annual formulary negotiations.

For any patient whose Medicaid claim is denied, the Amgen patient assistance program (see the next section) is the most direct alternative to explore before abandoning therapy entirely. The Institute for Clinical and Economic Review (ICER) has published value assessments noting that at a price point near $200 to $300 per month, evolocumab would meet conventional cost-effectiveness thresholds of $150,000 per quality-adjusted life year for high-risk patients [7].

Amgen Patient Assistance and Savings Card Programs for Oklahoma Residents

Amgen operates two distinct financial assistance pathways that Oklahoma patients should know about before concluding they cannot afford Repatha.

Amgen FIRST STEP Program. This is a free 30-day supply program for patients who are new to Repatha and are uninsured or underinsured. Eligibility is assessed at enrollment, and the program is accessible through a prescribing physician's office or directly through Amgen's support line [8].

Repatha Copay Card (commercial insurance only). For patients with private commercial insurance, the Amgen savings card can reduce monthly copays to as low as $0 per month, subject to a cap of $3,600 per calendar year in savings. Government-insured patients (Medicare, Medicaid, TRICARE) are not eligible. Oklahoma residents with employer-sponsored health insurance or individual marketplace plans should verify eligibility at the Amgen Repatha support page [8].

Amgen Assist 360. This broader patient support program helps with prior authorization, appeal letters, and connecting patients to independent nonprofit foundations such as the Patient Advocate Foundation and PAN Foundation, both of which maintain cardiovascular disease funds that can cover PCSK9 inhibitor costs for qualifying low-income patients [9].

A practical clinical point: the savings card works only when the drug is actually covered, even at a non-preferred tier, by the patient's commercial plan. If the plan excludes the drug entirely, the savings card cannot be applied. In that case, a 503A compounded option (described below) or full manufacturer assistance becomes the relevant pathway.

Is Compounded Evolocumab Legal in Oklahoma?

Compounded evolocumab is legally available in Oklahoma through 503A compounding pharmacies. This matters because the cost difference is substantial. A licensed 503A pharmacy can prepare evolocumab at a fraction of the branded Repatha price, sometimes at effectively zero net cost to the patient depending on the pharmacy's pricing model and any applicable assistance. The brand list price of $580 per month contrasts sharply with compounded versions that some 503A pharmacies price at well under $100 per month or supply under specific patient assistance arrangements.

A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding drugs for individual patients based on a valid prescription from a licensed prescriber [10]. Oklahoma's State Board of Pharmacy licenses and inspects 503A compounding facilities operating within the state and recognizes prescriptions sent to out-of-state 503A pharmacies when those pharmacies hold appropriate licensure in their home state and comply with Oklahoma's reciprocity provisions [11].

The critical legal distinction is between 503A (patient-specific, prescription-based compounding) and 503B (outsourcing facilities that compound in bulk without patient-specific prescriptions). PCSK9 inhibitor biologics like evolocumab are not on the FDA's 503B drug shortage list, which means bulk compounding through 503B facilities is not supported. Prescriptions routed to licensed 503A pharmacies for individual patients, by contrast, sit within the established legal framework as of 2026 [10].

Patients and prescribers should verify that any compounding pharmacy they use holds a current Oklahoma Board of Pharmacy license or a valid non-resident pharmacy permit. The quality of the compounded product depends on the pharmacy's adherence to USP <797> sterile compounding standards. A prescriber should confirm that the compounding pharmacy can demonstrate compliance with those standards before directing a patient there.

The FDA has not approved any compounded version of evolocumab, and the agency has noted general cautions about biologic compounding. Prescribers and patients should weigh the absence of approved-manufacturer quality controls against the access and cost benefit on a case-by-case basis [2].

Telehealth Prescribing of Repatha in Oklahoma

Oklahoma permits telehealth prescribing of non-controlled prescription medications, and evolocumab falls clearly outside the controlled substance schedules. A board-certified physician or nurse practitioner practicing via a telehealth platform can evaluate a patient's lipid panel, cardiovascular risk profile, and statin history remotely, then issue a valid Oklahoma prescription for evolocumab without an in-person visit [12].

The Oklahoma State Department of Health and the Oklahoma Medical Board extended and codified telehealth prescribing standards in the post-pandemic period. The prescriber must establish a valid patient-provider relationship before issuing the prescription, which in practice means a synchronous video visit, review of labs, and documentation of clinical indication [12].

For Oklahoma patients in rural counties, where access to a cardiologist or lipidologist may require a 90-mile drive, telehealth represents a practical access point. A 2022 study in the Journal of the American Heart Association found that telehealth cardiology visits produced equivalent lipid-management outcomes to in-person visits for patients with established ASCVD [13]. That evidence supports telehealth as a clinically sound prescribing pathway, not merely a convenience workaround.

Once a telehealth prescriber issues the Repatha prescription, the patient can route it to any licensed Oklahoma retail pharmacy, mail-order pharmacy through their insurer, or a licensed 503A compounding pharmacy if cost is the primary barrier.

Which Insurance Plans Cover Repatha in Oklahoma?

Coverage in Oklahoma's commercial market varies considerably by plan type and formulary year.

Employer-sponsored plans. Many large employer plans in Oklahoma include evolocumab on a specialty tier (Tier 4 or Tier 5), with monthly cost-sharing that can range from $50 to $400 depending on plan design. The Amgen savings card typically offsets that cost to near zero for eligible patients [8].

Oklahoma individual and small-group marketplace plans. ACA marketplace plans sold through Healthcare.gov for 2026 are required to cover preventive services at no cost but are not required to cover specialty drugs at any specific tier. Evolocumab appears on some formularies as a non-preferred specialty drug, requiring prior authorization and step therapy (documented statin failure and, in many plans, prior ezetimibe failure) [14].

Medicare Part D. Medicare beneficiaries in Oklahoma must check their specific plan's formulary each year. The Inflation Reduction Act's $2,000 out-of-pocket cap for Part D enrollees, effective January 2025, meaningfully reduces the annual ceiling for specialty drug costs including Repatha [15]. Patients who hit the cap pay nothing additional for covered drugs for the rest of the calendar year.

Medicare Advantage. MA plans in Oklahoma vary widely. Blue Cross Blue Shield of Oklahoma, Aetna, UnitedHealthcare, and Humana all operate MA plans in the state. Each maintains its own drug formulary. Patients should use the Medicare Plan Finder at medicare.gov to compare plans that include evolocumab on formulary before selecting coverage for the plan year.

TRICARE and VA. TRICARE covers PCSK9 inhibitors through the military pharmacy benefit with standard cost-sharing. The VA covers evolocumab under its national formulary for veterans who meet ASCVD or familial hypercholesterolemia criteria and have documented statin intolerance or inadequate LDL-C control on maximum-dose statin plus ezetimibe [16].

How to Get the Best Price on Repatha in Oklahoma: A Practical Decision Path

The cheapest path depends on a patient's insurance status and clinical situation. The following framework applies to most Oklahoma patients in 2026.

Step 1. Check your formulary first. Ask your pharmacist or log into your insurer's member portal to determine whether evolocumab is covered at any tier. If it is covered, the Amgen savings card will likely reduce your share to near zero. Contact Amgen Assist 360 to activate the card [8].

Step 2. If uninsured or if your plan excludes the drug entirely. Apply for the Amgen FIRST STEP free trial month while simultaneously applying for the full Amgen patient assistance program. Income-based eligibility for free product through Amgen typically requires a household income at or below 600% of the federal poverty level. The application is processed through the prescribing physician's office [8].

Step 3. If income exceeds manufacturer assistance thresholds. Ask your prescriber to route the prescription to a licensed 503A compounding pharmacy that compounds evolocumab. Confirm the pharmacy holds a current Oklahoma Board of Pharmacy license or a valid non-resident permit, and confirm USP <797> compliance before starting therapy [10].

Step 4. If on Medicare. Do not use the Amgen savings card (government beneficiaries are ineligible). Instead, apply to the PAN Foundation Cardiovascular Disease Fund or the HealthWell Foundation, both of which offer grants specifically for Part D cost-sharing on PCSK9 inhibitors [9]. Medicare's $2,000 Part D cap also provides a meaningful ceiling [15].

Step 5. Appeal a prior authorization denial. A denied PA is not a final answer. The ACC/AHA 2019 guidelines explicitly endorse PCSK9 inhibitors for very-high-risk patients with LDL-C >70 mg/dL on maximally tolerated statin plus ezetimibe [4]. A prescriber's appeal letter citing FOURIER cardiovascular outcome data [3] and guideline text carries meaningful weight in formal appeals.

Clinical Background: Why Evolocumab Gets Prescribed

Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab increases LDL receptor recycling, which pulls more LDL-C out of circulation. The mechanism is distinct from statins, which reduce cholesterol synthesis, and additive LDL-C lowering occurs when both drug classes are combined [3].

The FOURIER trial randomized 27,564 patients with established cardiovascular disease and LDL-C >70 mg/dL on optimized statin therapy to evolocumab 140 mg every two weeks or 420 mg monthly versus placebo. At 48 weeks, mean LDL-C fell from 92 mg/dL to 30 mg/dL in the evolocumab group, a 59% reduction (P<0.001) [3]. The trial met its primary endpoint, a 15% relative risk reduction in the composite of cardiovascular death, myocardial infarction, stroke, unstable angina, and coronary revascularization [3].

A secondary analysis of FOURIER published in Circulation found that patients with the highest baseline cardiovascular risk derived the largest absolute benefit, with a number needed to treat of 24 over three years in the highest-risk quintile [17]. That NNT compares favorably with many other preventive cardiovascular interventions and supports aggressive access efforts for high-risk Oklahoma patients facing cost barriers.

The FDA label also covers evolocumab for HoFH at a dose of 420 mg monthly, based on the TESLA Part B trial (N=49), which showed a 30.9% mean reduction in LDL-C compared to placebo (P<0.001) in this extremely high-risk genetic population [2, 18].

Injection-site tolerability is generally good. The most common adverse effects in FOURIER were nasopharyngitis (9.9% evolocumab vs. 9.5% placebo), upper respiratory infection (8.8% vs. 8.3%), and influenza-like illness. Neurocognitive events occurred at similar low rates in both groups [3]. The ACC/AHA guidelines note: "The safety profile of PCSK9 inhibitors has been favorable in large clinical trials with follow-up now exceeding three years" [4].

Monitoring and Ongoing Care for Oklahoma Patients on Evolocumab

A prescriber initiating evolocumab should obtain a fasting lipid panel four to eight weeks after the first dose to confirm the LDL-C response. The target for most very-high-risk patients under current guidelines is LDL-C <70 mg/dL, and many evolocumab patients reach LDL-C <40 mg/dL, which has not been associated with harm in FOURIER follow-up data [3, 4].

Liver function testing is not routinely required at initiation, unlike with statins, because evolocumab does not alter hepatic enzyme production pathways in the same way. Creatine kinase monitoring is similarly not standard unless the patient reports myalgia, since evolocumab is not associated with statin-type myopathy [2].

Self-injection training is available through Amgen's nurse educator program, accessible through Assist 360, or through most specialty pharmacies that dispense Repatha. The SureClick autoinjector and the prefilled syringe both require subcutaneous injection into the abdomen, thigh, or upper arm. Refrigerated storage at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) is required; the drug can be stored at room temperature for up to 30 days [2].

Annual reassessment of lipid goals, cardiovascular risk reclassification, and formulary status is standard practice. Oklahoma patients should confirm their insurance plan's formulary status each November during open enrollment to avoid mid-year coverage disruptions.